Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

News & Events

Wal-yan Centre welcomes Professor André Schultz as new Head

In an exciting development for the Wal-yan Respiratory Research Centre, Professor André Schultz has been appointed as the Centre’s new Head, succeeding Professor Stephen Stick. 

START Phage WA

START Phage WA was formed to pave the way towards treating AMR infections with phage therapy in Western Australia.

Working with the community

Community involvement plays an integral role in guiding our research - find out how.

Western Australian Epithelial Research Program

The Western Australian Epithelial Research Program (WAERP) is a community cohort biobank that collects and stores airway cells from the upper (nose) and lower (trachea) airways of Western Australian children and adults (1-50 years of age) undergoing non respiratory elective surgery.

Current Studies

The Western Australian Epithelial Research Program (WAERP) biobank is undertaking a number of research projects intended to improve the understanding and preclinical assessment of therapeutics for respiratory conditions.

Research

A phase I clinical trial assessing the safety, tolerability, and pharmacokinetics of inhaled ethanol in humans as a potential treatment for respiratory tract infections

Current treatments for respiratory infections are severely limited. Ethanol's unique properties including antimicrobial, immunomodulatory, and surfactant-like activity make it a promising candidate treatment for respiratory infections if it can be delivered safely to the airway by inhalation. Here, we explore the safety, tolerability, and pharmacokinetics of inhaled ethanol in a phase I clinical trial.

Research

The measurement properties of tests and tools used in cystic fibrosis studies: a systematic review

There is no consensus on how best to measure responses to interventions among children and adults with cystic fibrosis (CF). We have systematically reviewed and summarised the characteristics and measurement properties of tests and tools that have been used to capture outcomes in studies among people with CF, including their reliability, validity and responsiveness. This review is intended to guide researchers when selecting tests or tools for measuring treatment effects in CF trials. A consensus set of these tests and tools could improve consistency in how outcomes are captured and thereby facilitate comparisons and synthesis of evidence across studies.

Research

No association between in utero exposure to emissions from a coalmine fire and post-natal lung function

Studies linking early life exposure to air pollution and subsequent impaired lung health have focused on chronic, low-level exposures in urban settings. We aimed to determine whether in utero exposure to an acute, high-intensity air pollution episode impaired lung function 7-years later.

Research

The effect of CFTR modulators on structural lung disease in cystic fibrosis

Newly developed quantitative chest computed tomography (CT) outcomes designed specifically to assess structural abnormalities related to cystic fibrosis (CF) lung disease are now available. CFTR modulators potentially can reduce some structural lung abnormalities. We aimed to investigate the effect of CFTR modulators on structural lung disease progression using different quantitative CT analysis methods specific for people with CF (PwCF).

Research

The SPEC score—A quantifiable CT scoring system for primary ciliary dyskinesia

Structural lung changes seen on computed tomography scans in persons with primary ciliary dyskinesia are currently described using cystic fibrosis derived scoring systems. Recent work has shown structural changes and frequencies that are unique to PCD, indicating the need for a unique PCD-derived scoring system.